Wu, Chi JungChi JungWuLiu, Wei LunWei LunLiuLai, Chih ChengChih ChengLaiChao, Chien MingChien MingChaoKo, Wen ChienWen ChienKoWang, Hsuan ChenHsuan ChenWangDai, Ching TzuChing TzuDaiHsieh, Ming I.Ming I.HsiehChoi, Pui ChingPui ChingChoiYang, Jia LingJia LingYangYEE-CHUN CHEN2020-07-142020-07-142020-04-0110806040https://scholars.lib.ntu.edu.tw/handle/123456789/510019© 2020 Centers for Disease Control and Prevention (CDC). All rights reserved. In a multicenter study, we determined a prevalence rate of 4% for azole-resistant Aspergillus fumigatus in Taiwan. Resistance emerged mainly from the environment (TR34/ L98H, TR34/L98H/S297T/F495I, and TR46/Y121F/T289A mutations) but occasionally during azole treatment. A high mortality rate observed for azole-resistant aspergillosis necessitates diagnostic stewardship in healthcare and antifungal stewardship in the environment.animation[SDGs]SDG3cdr1b protein; difenoconazole; fungal protein; high mobility group B1 protein; pyrrole; sterol 14alpha demethylase; tebuconazole; unclassified drug; voriconazole; antifungal agent; fungal protein; pyrrole derivative; antifungal resistance; antifungal susceptibility; Article; aspergillosis; Aspergillus fumigatus; bacterium isolation; cross resistance; fungal colonization; gene mutation; genotype; human; lung aspergillosis; major clinical study; mortality rate; nonhuman; phylogeny; prevalence; Taiwan; antifungal resistance; Aspergillus fumigatus; clinical trial; epidemiology; genetics; microbial sensitivity test; multicenter study; Antifungal Agents; Aspergillus fumigatus; Azoles; Drug Resistance, Fungal; Fungal Proteins; Microbial Sensitivity Tests; Taiwanjournal article10.3201/eid2604.190840321865082-s2.0-85082024122WOS:000524156300031https://api.elsevier.com/content/abstract/scopus_id/85082024122